La cadena de opciones muestra datos clave de las opciones de acciones de Thermo Fisher Scientific a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Thermo Fisher Scientific..

Thermo Fisher Scientific (NYSE:TMO) Bolsa, Cadena de Opciones

THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Tomoe Engineering Co Ltd

Trimol Group Inc

Wall Street closed the week higher, with tech-heavy indices notching fresh records as upbeat corporate earnings, resilient macro data and breakthrough trade deals converged <a href="https://www.benzinga.com/markets">to boost risk appetite.</a>
<ul class="wp-block-list">
<li>SPY ETF has rallied 5% over the past month.<a href="https://www.benzinga.com/quote/SPY"> See the chart here. </a></li>
</ul>
The U.S. finalized new trade agreements with Indonesia, the Philippines and Japan. The Tokyo deal was the most significant, locking in a reduction in tariffs on Japanese autos and goods from 25% to 15%, while Japan pledged $550 billion in investment and improved access <a href="https://www.benzinga.com/news/25/07/46587245/japan-bond-yields-trump-trade-deal">to American-made goods.</a>
A U.S.-EU trade deal is now reportedly close, expected to align with the Japan framework and potentially ease existing tariff rates ahead of the Aug. 1 deadline.
Separately, President Donald Trump signed an Executive Order to boost the U.S. artificial intelligence sector by promoting the export of full-stack AI systems to trusted global partners. The White House said the move is aimed at strengthening economic leadership and national security.
Among the week's strongest performers, Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) rallied over 12%, topping the leaderboard for large-cap stocks, followed by T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), up 9%.
Within the Magnificent Seven, Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) rose by 1% after delivering better-than-expected results and raising its 2025 capital expenditures (capex) outlook by $10 billion, reinforcing its commitment to scaling AI infrastructure.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) dropped 8.2% following cautious commentary from CEO Elon Musk, who warned that upcoming quarters could prove challenging amid rising <a href="https://www.benzinga.com/markets/tech/25/07/46626447/elon-musk-says-20-trillion-valuation-possible-for-tesla-even-as-second-quarter-earnings-show-sales-revenue-decline-extreme-execution-is-needed">costs and margin pressures.</a>
Economic indicators added fuel to the rally. U.S. business activity surprised to the upside, with the Composite Purchasing Managers&#8217; Index climbing to a seven-month high in July, helped by expansion in services and steady consumer strength.
Trump's push to influence monetary policy continued with an unannounced visit to the Federal Reserve's headquarters in Washington, D.C. — the first by a sitting president <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46633129/trumps-fed-visit-powell-interest-rates">in nearly 20 years.</a>
Wearing a hard hat alongside Fed Chair Jerome Powell, Trump criticized the central bank's renovation project, claiming costs had surged to $3.1 billion. Powell countered on the spot, clarifying that the real cost is closer to $2.5 billion, excluding unrelated construction.
Pressed on rate policy, Trump said, "I'd love to see him lower interest rates."
Markets now shift focus to the July 30 Fed meeting, where expectations remain anchored for a hold — but not without growing political heat.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

Analyst Ratings

Tech

ETFs

GOOGL

TMUS

TSLA

Trade Deals Fuel Wall Street Gains, Trump Renews Fed Attack: This Week In Markets

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 6.48% on an annualized basis producing an average annual return of 14.98%. Currently, Thermo Fisher Scientific has a market capitalization of $181.46 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,628.32 today based on a price of $481.00 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753461018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

UBS analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Neutral and raises the price target from $460 to $500.

Price Target

UBS Maintains Neutral on Thermo Fisher Scientific, Raises Price Target to $500

Raymond James analyst Andrew Cooper reiterates Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and raises the price target from $525 to $535.

Reiteration

Raymond James Reiterates Outperform on Thermo Fisher Scientific, Raises Price Target to $535

WIIM

Thermo Fisher Scientific shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $553 to $567. Also, Barclays raised its price target on the stock from $450 to $490.

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and lowers the price target from $570 to $565.

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Lowers Price Target to $565

Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Equal-Weight and raises the price target from $450 to $490.

Barclays Maintains Equal-Weight on Thermo Fisher Scientific, Raises Price Target to $490

Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and raises the price target from $553 to $567.

Baird Maintains Outperform on Thermo Fisher Scientific, Raises Price Target to $567

U.S. stock futures were fluctuating on Thursday after rallying on Wednesday. Futures of major benchmark indices were mixed.
Alphabet Inc. drove gains as Google Search alone brought in <a href="https://www.benzinga.com/markets/tech/25/07/46593735/google-ceo-sundar-pichai-shrugs-off-headling-grabbing-exits-amid-talent-war-hype-we-are-doing-very-well">$54.19 billion in the second quarter</a>, and it raised its capital expenditure forecast for 2025 to around $85 billion, citing &#8220;strong and growing demand&#8221; for its cloud products and services.
Meanwhile, Tesla Inc. dropped after the CEO, Elon Musk, and CFO Vaibhav Taneja warned about the projected impacts from President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/earnings/25/07/46592460/tesla-stock-drops-after-hours-analysts-lament-lack-of-clear-metrics-balance-sheet-pressure-and-legal-risks-elon-musk-gave-ton-of-ammunition-to-lawyers-suing-him">tax and spending package </a>and the end of the EV tax credit.
Additionally, Trump said that U.S. trading partners will see tariff rates <a href="https://www.benzinga.com/markets/tech/25/07/46593182/trump-signs-new-executive-orders-to-fast-track-ai-dominance-we-will-be-unstoppable-as-a-nation">ranging from 15% to 50%</a> at an AI summit hosted by the Hill &amp; Valley Forum and the &#8220;All-In&#8221; podcast. 
The 10-year Treasury bond yielded 4.40% and the two-year bond was at 3.89%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 97.4% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.31%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.07%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.34%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.32%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were slightly higher in premarket on Thursday. The SPY was up 0.0016% at $634.22, while the QQQ advanced 0.19% to $564.89, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Healthcare, industrials, and energy stocks were among the biggest gainers on the S&amp;P 500 on Wednesday, while utilities and consumer staples bucked the trend and closed lower. Overall, U.S. stocks settled higher, with the S&amp;P 500 recording its 12th record close of the year.
President Trump announced agreements with the Philippines, Indonesia, and, most notably, Japan, while the Financial Times reported an imminent U.S.-EU trade deal, expected to mirror the Tokyo framework. The U.S.-Japan pact raised the baseline tariff on Japanese goods to 15% from 10%, avoiding the previously threatened 25% level.
In corporate news, Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) reported better-than-expected second-quarter financial results on Wednesday.
AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) also announced strong financial results for its fiscal second quarter of 2025, surpassing analyst expectations for both revenue and earnings.
On the economic data front, U.S. existing-home sales declined 2.7% from the previous month to an annual rate of 3.93 million units in June.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.61%</td>
<td>21,020.02</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.78%</td>
<td>6,358.91</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.14%</td>
<td>45,010.29</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.53%</td>
<td>2,283.13</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Despite a recent uptick in performance, the fundamentals do not support a favorable rating on U.S. small-cap equities, according to Scott Wren, Senior Global Market Strategist at Wells Fargo Investment Institute. Wren expressed a cautious stance, advising clients to temper expectations for the asset class for the remainder of 2025 and into 2026.
&#8220;We do not believe the fundamentals support a favorable rating on U.S. Small Cap Equities,&#8221; stated Wren, noting that many strategists have struggled to accurately time a resurgence in small-cap stocks relative to their large-cap counterparts over the past few years.
The Russell 2000 Index, a key measure of small-cap performance, has seen a noticeable improvement since the S&amp;P 500 Index hit its year-low on April 7. Since then, the R2K has slightly outperformed the S&amp;P 500, rallying 27.7% compared to the latter&#8217;s 27.2% rise as of July 23.
This recent neck-and-neck performance has drawn attention, particularly given the S&amp;P 500&#8217;s significant outperformance over the past two years. Over the past four years, the S&amp;P 500 is up nearly 55% while the R2K is largely flat.
Wren attributes the historical underperformance and recent improvement to a combination of &#8220;poor fundamentals (in recent years) and market risk tolerance (more recently).&#8221; He elaborated that smaller-cap equities typically possess weaker balance sheets and are more sensitive to interest rates, relying heavily on credit.
Wells Fargo Investment Institute has maintained a neutral weighting for U.S. Small Cap Equities for nearly a year. While investors have recently gravitated towards small caps amid a &#8220;risk-on&#8221; mood and expectations for multiple Federal Reserve interest rate cuts this year, Wren stated, &#8220;We, on the other hand, have stuck with our recommendation to lean toward quality large-cap equities and look for the Fed to cut interest rates only one time this year.&#8221;
As a result, Wells Fargo suggests investors consider trimming their exposure to U.S. Small Cap Equities, either holding those funds for future reinvestment at lower levels or reallocating them to favored sectors that have recently underperformed, such as Energy, Utilities, and Financials.
Meanwhile, Ryan Detrick of Carson Research highlighted that July 2025 was going to match an old record from 1950 to 1961 when the S&amp;P 500 index was up for 11 consecutive Julys. This July would mark the 11th consecutive year as well, starting from 2014.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With a week to go, the S&amp;P 500 is up a very solid 2.5% in July. This would be the 11th consecutive year stocks were higher in July, tying the longest win streak ever. <a href="https://t.co/5WU1FviJBG">pic.twitter.com/5WU1FviJBG</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1948117334314357165?ref_src=twsrc%5Etfw">July 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul class="wp-block-list">
<li>The initial jobless claims data for the week ended July 19 will be announced by 8:30 a.m. ET.</li>
</ul>
<ul class="wp-block-list">
<li>July&#8217;s S&amp;P flash U.S. services and manufacturing PMI will be out by 9:45 a.m., and June&#8217;s new home sales data will be released by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) tumbled 6.09% in premarket on Thursday after reporting weaker-than-expected second-quarter financial results. Its revenue of $22.5 billion was down 12% year-over-year. It missed a Street consensus estimate of $22.8 billion. Its earnings per share were $0.40 in the quarter, missing the Street consensus estimate of $0.42 per share.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) rose 2.89% after reporting better-than-expected second-quarter financial results and increasing its investment in capital expenditures in 2025. Its second-quarter revenue of $96.43 billion beat analyst estimates of $93.72 billion. Its earnings of $2.31 per share beat estimates of $2.16 per share.</li>
<li>American Eagle Outfitters Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) jumped 16.08% following the launch of a new advertising campaign featuring actress Sydney Sweeney.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) was up 0.43% as analysts expect it to report earnings of 1 cent per share on revenue of $11.91 billion after the closing bell.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) was down 0.79% as it is expected to report earnings before the opening bell. Analysts estimate earnings of 77 cents per share on revenue of $14.30 billion.</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) advanced 1.12% as analysts expect it to report earnings of $2.65 per share on revenue of $10.02 billion before the opening bell.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) zoomed 8.73% continuing to be driven by retail investor hype and viral buzz across and notable backing from Eric Jackson, founder of EMJ Capital.</li>
<li>Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) dropped 10.44% as its earnings per share exceeded expectations by $0.01, but its revenue fell short of estimates. The company also adjusted its 2025 same-store sales forecast to be flat, which led to the stock price decline.</li>
<li>T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) rose 5.16% after a robust second-quarter earnings and the launch of T-Satellite in partnership with Satrlink.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.15% to hover around $66.00 per barrel.
Gold Spot US Dollar fell 0.59% to hover around $3,367.29 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.14% at the 97.3490 level.
Asian markets ended on a mixed note on Thursday as Japan's Nikkei 225, South Korea's Kospi, Hong Kong's Hang Seng, and China&#8217;s CSI 300 indices advanced. However, India's S&amp;P BSE Sensex and Australia's ASX 200 indices fell. European markets were higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46594057/trumps-big-beautiful-bill-fuels-atts-5g-fiber-expansion-we-intend-to-invest-more-rapidly-in-next-generation-networks">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Fuels AT&amp;T&#8217;s 5G, Fiber Expansion: &#8216;We Intend To Invest More Rapidly In Next Generation Networks&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

GOOG

INTC

OPEN

US Stocks Likely To Open On A Mixed Note After Tesla, Alphabet Earnings: Intel, American Airlines, Honeywell In Focus

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the &#8220;Extreme Greed&#8221; zone on Wednesday.
U.S. stocks settled higher on Wednesday, with the Dow Jones index gaining more than 500 points during the session. The S&amp;P 500 also logged its 12th record close of the year.
President Donald Trump announced agreements with the Philippines, Indonesia and—most significantly—Japan, while the Financial Times reported that a U.S.-EU trade deal is imminent, expected to mirror the Tokyo framework.
The U.S.-Japan pact raises the baseline tariff on Japanese goods to 15% from 10%, sidestepping the previously threatened 25% level.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) reported better-than-expected second-quarter financial results on Wednesday. AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) announced strong financial results for its fiscal second quarter of 2025 on Wednesday, surpassing analyst expectations for both revenue and earnings.
On the economic data front, U.S. existing-home sales declined 2.7% from the previous month to an annual rate of 3.93 million units in June.
Most sectors on the S&amp;P 500 closed on a positive note, with healthcare, industrials, and energy stocks recording the biggest gains on Wednesday. However, utilities and consumer staples stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by 508 points to 45,010.29 on Wednesday. The S&amp;P 500 gained 0.78% to 6,358.91, while the Nasdaq Composite gained 0.61% at 21,020.02 during Wednesday's session.
Investors are awaiting earnings results from Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 76.3, the index moved to the &#8220;Extreme Greed&#8221; zone on Wednesday, versus a prior reading of 73.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Dow Surges 500 Points Amid Trump's Trade Deal Deluge: Investor Sentiment Improves, Fear Index Moves To 'Extreme Greed' Zone

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday.
The Dow traded up 0.82% to 44,869.16 while the NASDAQ rose 0.16% to 20,925.86. The S&amp;P 500 also rose, gaining, 0.44% to 6,337.46.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a>
Leading and Lagging Sectors Industrials shares jumped by 1.1% on Wednesday.
In trading on Wednesday, utilities stocks dipped by 0.3%.
Top Headline
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) reported better-than-expected second-quarter financial results.
Thermo Fisher Scientific posted adjusted earnings of $5.36 per share, beating market estimates of $5.23 per share. The company's sales came in at $10.855 billion versus estimates of $10.684 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>ABIVAX Société Anonyme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) shares shot up 561% to $66.10 after the company announced that Obefazimod met all its key secondary endpoints. JMP Securities raised its price target on the stock from $33 to $39.</li>
<li>Shares of Alpha Modus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) got a boost, surging 60% to $1.8450 after the company announced it secured exclusive US rights to CashX kiosks.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) shares were also up, gaining 75% to $3.21 after the company announced a reverse stock split with a ratio of at least 1-for-2500.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) shares dropped 18% to $136.99 following second-quarter financial results. Additionally, the company announced it entered into an equity purchase agreement to acquire part of TD&#8217;s merchant processing business in Canada.</li>
<li>Shares of Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) were down 12% to $188.47 following second-quarter results.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) was down, falling 21% to $0.4124. The company announced the elimination of its series A preferred stock and its related obligations in exchange for 2.1 million common shares.</li>
</ul>
Commodities In commodity news, oil traded down 1.7% to $65.09 while gold traded down 0.6% at $3,422.60.
Silver traded up 0.4% to $39.715 on Wednesday, while copper rose 2.8% to $5.8805.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.08%, while Spain's IBEX 35 Index rose 0.16%. London's FTSE 100 gained 0.56%, Germany's DAX 40 rose 0.63% and France's CAC 40 climbed 1.38% during the session.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 surging 3.51%, Hong Kong's Hang Seng gaining 1.62%, China's Shanghai Composite gaining 0.01% and India's BSE Sensex rising 0.66%.
Economics
<ul class="wp-block-list">
<li>U.S. existing-home sales declined 2.7% from the previous month to an annual rate of 3.93 million units in June.</li>
<li>The volume of mortgage applications rose by 0.8% from the previous week during the third week of July.</li>
<li>U.S. crude oil inventories declined by 3.169 million barrels in the week ended July 18, compared to market estimates of a 1.6 million fall.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46571059/tesla-likely-to-report-lower-q2-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46571059/tesla-likely-to-report-lower-q2-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Tesla Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

Markets

ABVX

AMOD

ANEB

DFLI

Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views

Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the street view of $5.23</a>.
Quarterly sales of $10.86 billion increased 3% year-over-year, beating the analyst consensus estimate of $10.68 billion. Organic revenue growth was 2%.
&#8220;The agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base and deliver strong operational results in the second quarter,&#8221; said Marc Casper, chairman, president and <a href="https://www.benzinga.com/pressreleases/25/07/b46566528/thermo-fisher-scientific-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">CEO of Thermo Fisher Scientific</a>.
The company said, &#8220;PPI is helping us adjust our supply chains in the tariff environment and to actively manage our cost base.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/equities/25/05/45643874/thermo-fisher-scientific-stock-big-upside-potential-after-sluggishness-through-november" target="_blank" rel="noreferrer noopener">Thermo Fisher Scientific Stock: Big Upside Potential After Sluggishness Through November?</a>
Management Change: Thermo Fisher Scientific announced Stephen Williamson, senior vice president and CFO, has decided to retire from the company, effective March 31, 2026.
The company&#8217;s board of directors appointed Jim Meyer, vice president of financial operations, to succeed Williamson as CFO, <a href="https://www.benzinga.com/pressreleases/25/07/b46570556/thermo-fisher-scientifics-chief-financial-officer-stephen-williamson-to-retire-in-early-2026" target="_blank" rel="noreferrer noopener">effective March 1, 2026</a>.
Guidance: During an earnings conference call, Thermo Fisher Scientific forecasts 2025 revenue of $43.6 billion-$44.2 billion, compared to prior guidance of $43.3 billion-$44.2 billion and the consensus of $43.71 billion.
The company expects adjusted earnings of $22.22-$22.84&nbsp;per share, compared to <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966173/thermo-fisher-beats-q1-estimates-lowers-full-year-forecast-as-tariffs-and-costs-take-a-toll" rel="noreferrer noopener">prior guidance of $21.76-$22.84</a> and consensus of $22.33. The company adds that the U.S.-China tariff situation has improved significantly compared to prior assumptions.
Last week, Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) to enable additional U.S. drug product manufacturing. The terms of the deal <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46439260/thermo-fisher-scientific-and-sanofi-expand-strategic-partnership-to-enable-additional-u-s-drug-pro" rel="noreferrer noopener">were not disclosed</a>.
Under the agreement, Thermo Fisher will acquire Sanofi&#8217;s steriles manufacturing site in Ridgefield, New Jersey, and continue to manufacture a portfolio of therapies for Sanofi.
In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.
The Ridgefield site is a sterile fill-finish and packaging facility with over 200 employees who will join Thermo Fisher following the completion of the transaction.
The transaction is expected to be completed in the second half of 2025. Upon completion of the transaction, Sanofi&#8217;s Ridgefield facility will become part of Thermo Fisher&#8217;s pharma services business within its Laboratory Products and Biopharma Services segment.
Price Action: TMO stock is up 13.2% at $483.94 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46568747/carvana-stock-outlook-cautious-optimism-warranted" target="_blank" rel="noreferrer noopener">Carvana Stock Outlook: Cautious Optimism Warranted</a></li>
</ul>
Photo: Shutterstock

Guidance

Health Care

Management

Movers

General

Why Thermo Fischer Stock Is Rising Wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday.
Shares of GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and <a href="https://www.benzinga.com/markets/earnings/25/07/46570983/ge-vernova-lifts-outlook-as-revenue-and-orders-surge">raised its full-year guidance</a>.
The energy transition company reported second-quarter earnings per share of $1.86, beating the consensus estimate of $1.69. Revenue came in at $9.11 billion, exceeding Wall Street's expectations of $8.78 billion.
GE Vernova shares climbed 13.5% to $623.10 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>ABIVAX Société Anonyme (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) shares jumped 548% to $66.13 after the company announced that Obefazimod met all its key secondary endpoints. JMP Securities raised its price target on the stock from $33 to $39.</li>
<li>aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) gained 31.7% to $6.90.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) rose 28% to $4.0050. Chardan Capital maintained a Buy rating on the stock.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 23% to $16.73.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) jumped 19.6% to $58.78 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) rose 19.2% to $124.93 after the company reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Vicor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) rose 18.7% to $53.66 following second-quarter results.</li>
<li>Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) gained 18.5% to $13.34 after the company and Oklo announced an alliance to offer an integrated deployment strategy.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) rose 18% to $2.7150 after the company announced the first Symvess sale to a U.S. military treatment facility.</li>
<li>Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) climbed 17.5% to $7.32.</li>
<li>Krispy Kreme, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) gained 16.2% to $4.80. The stock's sudden rise appears to be driven by retail investors, with the company gaining increased attention on various social media platforms.</li>
<li>Toyota Motor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) climbed 13.3% to $192.68. Shares of US-listed Japanese stocks traded higher after President Trump announced a trade deal with Japan.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) rose 12.7% to $481.78 after the company reported better-than-expected quarterly financial results.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 12.5% to $34.19. Shares of US-listed Japanese stocks traded higher after President Trump announced a trade deal with Japan.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) rose 10% to $56.03 after the company reported second-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) gained 10% to $223.06 after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) jumped 10% to $682.00 following upbeat second-quarter results.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) jumped 9.8% to $16.43 fter the company issued a statement reaffirming the strength of its exclusive license and collaboration agreement with Sarepta Therapeutics.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) rose 9.6% to $10.16.</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) gained 6.4% to $316.80 after the company reported better-than-expected second-quarter financial results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46541326/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

ARWR

ATYR

CALM

DNUT

HUMA

IOVA

LBRT

MANH

PEGA

STLA

VALN

VICR

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday

During Conf Call, Thermo Fisher Scientific Forecasts 2025 Revenue To Be In The Range Of $43.6B-$44.2B; 2025 Adj EPS To Be In The Range Of $22.22-$22.84 Per Share; Says The U.S. China Tariff Situation Has Improved Significantly Versus Our Prior Guidance Assumptions

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026.

Thermo Fisher Scientific Appoints Jim Meyer As CFO, effective March 1, 2026, Succeeding Stephen Williamson

Thermo Fisher Scientific shares are trading higher after the company reported better-than-expected Q2 financial results.

Thermo Fisher Scientific Q2 2025 Adj. EPS $5.36 Beats $5.23 Estimate, Sales $10.855B Beat $10.684B Estimate

AMTB

ASGN

BANC

BPOP

BRKL

CADE

CBAN

CHDN

COOP

CSBR

CVBF

CVLG

EGBN

EPRT

EQNR

ESRT

First Trust Advantage Preferred Income Fund

FRME

FSBC

GLPG

GSHD

HBNC

HCSG

ICLR

INBK

KALU

MTAL

NTRS

NTST

NVEC

ORLY

OTIS

OTLY

OXLC

PLXS

PTEN

QCRH

RBBN

RELL

SEIC

SIGI

Earnings Scheduled For July 23, 2025

Financial giants have made a conspicuous bullish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) revealed 49 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 20 were puts, with a value of $2,571,663, and 29 were calls, valued at $2,836,471.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $330.0 to $470.0 for Thermo Fisher Scientific over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Thermo Fisher Scientific's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Thermo Fisher Scientific's significant trades, within a strike price range of $330.0 to $470.0, over the past month.
<h3>Thermo Fisher Scientific 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753214439_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$22.6</td>
<td>$21.1</td>
<td>$21.8</td>
<td>$420.00</td>
<td>$1.6M</td>
<td>92</td>
<td>763</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.1</td>
<td>$7.7</td>
<td>$7.7</td>
<td>$470.00</td>
<td>$385.0K</td>
<td>416</td>
<td>526</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$15.0</td>
<td>$14.9</td>
<td>$15.0</td>
<td>$420.00</td>
<td>$325.5K</td>
<td>1.0K</td>
<td>365</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$15.4</td>
<td>$14.7</td>
<td>$15.4</td>
<td>$420.00</td>
<td>$209.4K</td>
<td>1.0K</td>
<td>560</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$17.7</td>
<td>$16.9</td>
<td>$17.7</td>
<td>$420.00</td>
<td>$173.4K</td>
<td>1.0K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Having examined the options trading patterns of Thermo Fisher Scientific, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>Currently trading with a volume of 2,776,071, the TMO's price is up by 0.27%, now at $406.05. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What The Experts Say On Thermo Fisher Scientific</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $506.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Thermo Fisher Scientific, maintaining a target price of $450. 
&#x2A; An analyst from Scotiabank upgraded its action to Sector Outperform with a price target of $590. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Thermo Fisher Scientific, which currently sits at a price target of $553. 
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Neutral, setting a price target of $460. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Thermo Fisher Scientific, which currently sits at a price target of $480. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Thermo Fisher Scientific, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Behind the Scenes of Thermo Fisher Scientific's Latest Options Trends

AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) announced on Tuesday that it will invest $50 billion in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">United States by 2030</a>.
The investment will create new, highly skilled direct and indirect jobs nationwide, the company <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html" rel="noreferrer noopener">said</a>.
The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.
The new centre will produce small molecules, peptides, and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.
<h2 class="wp-block-heading">What Does The Investment Include?</h2>
The $50 billion investment across R&amp;D and manufacturing footprint in the U.S. over the next five years also includes:
<ul class="wp-block-list">
<li>Expansion of R&amp;D facility in Gaithersburg, Maryland</li>
<li>R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li>
<li>Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials.</li>
</ul>
The company said collectively, these investments will help deliver AstraZeneca's <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">ambition of reaching $80 billion</a> in Total Revenue by 2030, of which 50% would be generated in the U.S.
Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."
<a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46529101/biogen-bets-big-on-2-billion-expansion-to-boost-us-drug-manufacturing" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" rel="noreferrer noopener">the next four years</a>.
Medtech firm&nbsp;Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>. Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/pharmaceuticals" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer,&nbsp;<a target="_blank" href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years. Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced it will invest at least&nbsp;$20 billion&nbsp;in&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" rel="noreferrer noopener">U.S.&nbsp;through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46551856/pony-ai-stock-surges-as-autonomous-system-hits-key-milestone" target="_blank" rel="noreferrer noopener">Pony AI Stock Surges As Autonomous System Hits Key Milestone</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Biotech

BIIB

REGN

RHHBY

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

Press Releases

Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

908 Devices Appoints Christopher D. Brown to its Board of Directors

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

Thermo Fisher Scientific Reports Second Quarter 2025 Results

Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

AAPL

MASS

RGEN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Raymond James

Wells Fargo

Barclays

Baird

Screenshot 2025-04-15 at 7.03.21 PM

MYNZ

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Thermo Fisher Scientific

Thermo Fisher Scientific (TMO) Opciones

Thermo Fisher Scientific (NYSE:TMO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL